(function(){
			var content_array=["<p><strong>About DAWN2&trade;<\/strong><\/p>\r\n<p>DAWN2&trade; is a global Novo Nordisk initiative conducted in collaboration with the IDF, the International Alliance of Patients' Organizations (IAPO), the Steno Diabetes Center and a range of other national, regional and global partners. The DAWN2&trade; results highlight opportunities for improving diabetes care, education and community support by putting people with diabetes and their families centre stage. The DAWN2&trade; study will be used internationally and nationally to facilitate dialogue among patient organisations, healthcare professionals and other key stakeholders to develop action plans for improvement of the lives of people with diabetes. Further information is available at&nbsp;<a rel=\"nofollow\" href=\"http:\/\/www.dawnstudy.com\" target=\"_blank\">http:\/\/www.dawnstudy.com<\/a>.<\/p>\r\n<p><strong>About Novo Nordisk<\/strong><\/p>\r\n<p><em>Headquartered in Denmark,<\/em>&nbsp;<em>Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care,<\/em>&nbsp;<em>growth hormone therapy and hormone replacement therapy. Novo Nordisk employs approximately 37,000 employees in 75 countries,<\/em>&nbsp;<em>and markets its products in more than 180 countries. For more information,<\/em>&nbsp;<em>visit <a rel=\"nofollow\" href=\"http:\/\/www.novonordisk.com\/default.asp\" target=\"_blank\">novonordisk.com<\/a>.<\/em><\/p>\r\n<p>Further information<\/p>\r\n<p><em>Media:<\/em><br \/>Daniel Vamosi Martinussen<br \/>+45-3079-1879<br \/><a rel=\"nofollow\" href=\"mailto:dvmm@novonordisk.com\" target=\"_blank\">dvmm@novonordisk.com<\/a><\/p>\r\n<p>Ken Inchausti (US)<br \/>+1-609-514-8316<br \/><a rel=\"nofollow\" href=\"mailto:kiau@novonordisk.com\" target=\"_blank\">kiau@novonordisk.com<\/a><\/p>\r\n<p><em>Investors:<\/em><br \/>Kasper Roseeuw Poulsen<br \/>+45-4442-4303<br \/><a rel=\"nofollow\" href=\"mailto:krop@novonordisk.com\" target=\"_blank\">krop@novonordisk.com<\/a><\/p>\r\n<p>Frank Daniel Mersebach<br \/>+45-4442-0604<br \/><a rel=\"nofollow\" href=\"mailto:fdni@novonordisk.com\" target=\"_blank\">fdni@novonordisk.com<\/a><\/p>\r\n<p>Daniel Bohsen<br \/>+45-3079-6376<br \/><a rel=\"nofollow\" href=\"mailto:dabo@novonordisk.com\" target=\"_blank\">dabo@novonordisk.com<\/a><\/p>\r\n<p>Lars Borup Jacobsen<br \/>+45-3075-3479<br \/><a rel=\"nofollow\" href=\"mailto:lbpj@novonordisk.com\" target=\"_blank\">lbpj@novonordisk.com<\/a><\/p>\r\n<p>Jannick Lindegaard (US)<br \/>+1-609-786-4575<br \/><a rel=\"nofollow\" href=\"mailto:jlis@novonordisk.com\" target=\"_blank\">jlis@novonordisk.com<\/a><\/p>\r\n<p><strong>References<\/strong><\/p>\r\n<p>1. I. Willaing, DAWN2&trade; Study Results: Involvement and Education. Oral Lecture, DAWN2&trade; Symposium, 5 December 2013, World Diabetes Congress of the International Diabetes Federation (IDF).<\/p>\r\n<p>Video:&nbsp;<a rel=\"nofollow\" href=\"http:\/\/www.multivu.com\/mnr\/64152-novo-nordisk-diabetes-report-doctor-treatment\" target=\"_blank\">http:\/\/www.multivu.com\/mnr\/64152-novo-nordisk-diabetes-report-doctor-treatment<\/a><\/p>"];
			$("#dvExtra").html(content_array[0]);})();